Evaluating prescriber preferences for the treatment of indeterminate Chagas disease (EPPIC study): an international survey

The EPPIC study was an international survey aimed at determining healthcare providers' preferences for treating Chagas disease caused by the parasite Trypanosoma cruzi. The survey included 30 respondents (60% response rate), mostly physicians and nurses with more than six years of experience. Results showed that efficacy of 70% and above was associated with substantially higher prescribing willingness – 46.7% of respondents would likely prescribe a regimen with 70–79% efficacy, compared to 20% for 60–69% and 6.7% for 50–59%. Willingness to prescribe regimens with moderate efficacy increased when they offered prevention of mother-to-child transmission, reduced adverse effects, or possibility of second-line use. Respondents identified adverse drug reactions, long treatment duration, and limited drug availability as the main disadvantages of current therapies.